BioSpace News Archive

Senseonics Holdings, Inc., a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes, announced plans to participate in the upcoming Sidoti Small Cap Conference, being held in virtually.

Enlivex Therapeutics Ltd. announced the closing of its previously announced registered direct offering to a single healthcare-focused institutional investor of an aggregate of 3,571,429 ordinary shares and clinical milestone-linked warrants.

Nuvation Bio Inc. (NYSE: NUVB) announced today that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will participate in a hybrid presentation at the Jefferies Global Healthcare Conference in New York, NY on Wednesday, June 5, 2024, at 1:30 p.m. ET.

Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.57 billion for the second quarter ended April 30, 2024, a decline of 8.4% reported and 7.4% core(1) compared to the second quarter of 2023.

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will participate in the following investor conferences in June.

Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, announced the election of the 10 directors nominated at its 2024 annual meeting of shareholders held on May 29, 2024.

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences.

Castle Biosciences, Inc. announced the publication of a study in the International Journal of Radiation Oncology • Biology • Physics demonstrating the ability of the DecisionDx-SCC test to identify high-risk cutaneous SCC patients at the highest risk of metastasis who will benefit the most from ART to reduce metastatic disease progression, as well as high-risk patients who the test identified as having a lower risk of metastasis who may consider deferring treatment.

Tarsus Pharmaceuticals, Inc., whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, announced that management will participate in the following conferences.

Zimmer Biomet Holdings, Inc., a global medical technology leader, hosted its 2024 Investor Day and provided an in-depth review of the Company’s strategic priorities and long-range plan for growth and value creation.